Skip to content
Search

Latest Stories

WHO unveils comprehensive guidelines to help millions quit tobacco

WHO unveils comprehensive guidelines to help millions quit tobacco
The new WHO guidelines on tobacco cessation aims to enhance global access to effective cessation aids, underscoring WHO's commitment to addressing disparities in healthcare access

"Combining pharmacotherapy with behavioural interventions significantly increases quitting success rates," new World Health Organization (WHO) guidelines on tobacco cessation highlight.

In a landmark move, the WHO has unveiled comprehensive guidelines to assist the more than 750 million people worldwide seeking to quit tobacco use.


This first-ever guideline on tobacco cessation advocates for a holistic approach, integrating behavioural support, digital interventions, and pharmacological treatments to address the  global health issue.

Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, highlighted the significance of these guidelines in the ongoing battle against tobacco-related diseases.

"This guideline marks a crucial milestone in our global battle against these dangerous products," he stated.

"It empowers countries with the essential tools to effectively support individuals in quitting tobacco and alleviate the global burden of tobacco-related diseases.."

Despite the widespread desire to quit tobacco, according to the WHO over 70 per cent of those attempting cessation lack access to adequate support services.

This is primarily due to resource constraints within healthcare systems.

The WHO's guideline have urged governments to prioritise accessibility by offering medications such as varenicline, Nicotine Replacement Therapy (NRT), bupropion, and cytisine at reduced or no cost, particularly in low- and middle-income countries.

Since initiating a prequalification procedure for tobacco cessation medications in 2023, the WHO has recently approved Kenvue's nicotine gum and patch as the first WHO-prequalified NRT products.

This step aims to enhance global access to effective cessation aids, underscoring WHO's commitment to addressing disparities in healthcare access.

Behavioural interventions also play a crucial role in the guidelines, advocating for brief counselling sessions in healthcare settings and more intensive support through individual, group, or telephonic counselling.

Digital interventions, such as smartphone applications and online programs, are recommended as additional support tools throughout the quitting process.

Dr. Rüdiger Krech, WHO's Director of Health Promotion, emphasised the collaborative effort required to tackle tobacco use.

"These guidelines are designed to empower communities and governments to provide the best possible support for individuals on this challenging journey," he stressed.

The release of WHO's comprehensive tobacco cessation guidelines represents a significant step towards reducing the global burden of tobacco-related diseases and improving public health worldwide.

Healthcare providers, policymakers, and stakeholders are urged to adopt and implement these guidelines to support millions in achieving tobacco-free lives.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less